FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2597431707> ?p ?o ?g. }

• W2597431707 endingPage "3027" @default.
• W2597431707 startingPage "3027" @default.
• W2597431707 abstract "3027 Background: Two rational strategies to interrogate the IGF-1R pathway were investigated in this parallel-arm phase I trial: 1) vertical inhibition with D and MK-2206 to potentiate PI3K pathway targeting, 2) horizontal crosstalk inhibition with D and MK-0752 to exert effects against cellular proliferation, angiogenesis and stem cell propagation. Methods: Patients (pts) with advanced solid tumors and no prior exposure to agents of the same targets were eligible. Dose escalation was based on a modified toxicity probability interval method (Ji et al, 2010). Arm A is comprised of fixed D dose of 10 mg/m2 IV weekly plus MK-2206 at escalating doses of 90-200 mg PO weekly. Arm B is comprised of fixed MK-0752 dose of 1800 mg PO weekly plus D at escalating doses of 7.5-10 mg/m2 IV weekly. Each cycle = 4 weeks in both arms. Primary objectives were to determine DLT and RP2D of these combinations. Results: 30 patients were enrolled in the dose escalation phase (18 in Arm A and 12 in Arm B) with: median age = 56 (range 36-74); M:F = 13:17; ECOG 0:1 = 12:18; primary diagnosis = colorectal (CRC) (9), NSCLC (3), others (17); prior metastatic regimens = 3 (range 1-4). In Arm A, 1/6 DLT was observed with MK-2206 at 135 mg (G3 serum sickness-like reaction); 2/3 DLTs with MK-2206 at 200 mg (G4 leukopenia/neutropenia; G3 rash). No other G4 or worse adverse events (AEs) were observed. RP2D of Arm A = D 10mg/m2 IV weekly and MK-2206 150 mg PO weekly. Other common AEs in Arm A included: fatigue, rash and nausea. In Arm B, 2/6 DLTs were observed with D at 10 mg/m2 (G3 rash; G3 nausea/vomiting). RP2D of Arm B = D 10mg/m2 IV weekly and MK-0752 at 1800 mg PO weekly based on Ji et al. Other common AEs in Arm B included: anorexia, nausea and fatigue. No PR was observed and SD > 4 months occurred in 4 pts (all in Arm A). PK analyses are ongoing. Conclusions: Targeted combinations of D with MK-2206 or with MK-0752 were both tolerable. Expansion cohorts based on biomarker selection are underway, specifically ovarian cancer with high IGF1 expression/low RAS score for Arm A; and KRAS wild-type CRC with high IGF1/low IGF2 expression for Arm B." @default.
• W2597431707 created "2017-04-07" @default.
• W2597431707 creator A5000204204 @default.
• W2597431707 creator A5007121755 @default.
• W2597431707 creator A5062199973 @default.
• W2597431707 creator A5062200767 @default.
• W2597431707 creator A5078820101 @default.
• W2597431707 creator A5079422406 @default.
• W2597431707 creator A5087483970 @default.
• W2597431707 creator A5089153267 @default.
• W2597431707 creator A5089998052 @default.
• W2597431707 date "2012-05-20" @default.
• W2597431707 modified "2023-09-26" @default.
• W2597431707 title "Rational molecularly targeted combinations: A parallel-arm phase I trial of the humanized anti-IGF-1R antibody dalotuzumab (D) in combination with the allosteric AKT inhibitor MK-2206 or the gamma secretase inhibitor MK-0752, in patients with advanced solid tumors." @default.
• W2597431707 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.3027" @default.
• W2597431707 hasPublicationYear "2012" @default.
• W2597431707 type Work @default.
• W2597431707 sameAs 2597431707 @default.
• W2597431707 citedByCount "1" @default.
• W2597431707 countsByYear W25974317072016 @default.
• W2597431707 crossrefType "journal-article" @default.
• W2597431707 hasAuthorship W2597431707A5000204204 @default.
• W2597431707 hasAuthorship W2597431707A5007121755 @default.
• W2597431707 hasAuthorship W2597431707A5062199973 @default.
• W2597431707 hasAuthorship W2597431707A5062200767 @default.
• W2597431707 hasAuthorship W2597431707A5078820101 @default.
• W2597431707 hasAuthorship W2597431707A5079422406 @default.
• W2597431707 hasAuthorship W2597431707A5087483970 @default.
• W2597431707 hasAuthorship W2597431707A5089153267 @default.
• W2597431707 hasAuthorship W2597431707A5089998052 @default.
• W2597431707 hasConcept C126322002 @default.
• W2597431707 hasConcept C143998085 @default.
• W2597431707 hasConcept C197934379 @default.
• W2597431707 hasConcept C2777063308 @default.
• W2597431707 hasConcept C2778570526 @default.
• W2597431707 hasConcept C2778850193 @default.
• W2597431707 hasConcept C2780873365 @default.
• W2597431707 hasConcept C29730261 @default.
• W2597431707 hasConcept C71924100 @default.
• W2597431707 hasConcept C90924648 @default.
• W2597431707 hasConcept C98274493 @default.
• W2597431707 hasConceptScore W2597431707C126322002 @default.
• W2597431707 hasConceptScore W2597431707C143998085 @default.
• W2597431707 hasConceptScore W2597431707C197934379 @default.
• W2597431707 hasConceptScore W2597431707C2777063308 @default.
• W2597431707 hasConceptScore W2597431707C2778570526 @default.
• W2597431707 hasConceptScore W2597431707C2778850193 @default.
• W2597431707 hasConceptScore W2597431707C2780873365 @default.
• W2597431707 hasConceptScore W2597431707C29730261 @default.
• W2597431707 hasConceptScore W2597431707C71924100 @default.
• W2597431707 hasConceptScore W2597431707C90924648 @default.
• W2597431707 hasConceptScore W2597431707C98274493 @default.
• W2597431707 hasIssue "15_suppl" @default.
• W2597431707 hasLocation W25974317071 @default.
• W2597431707 hasOpenAccess W2597431707 @default.
• W2597431707 hasPrimaryLocation W25974317071 @default.
• W2597431707 hasRelatedWork W1833952634 @default.
• W2597431707 hasRelatedWork W1997644069 @default.
• W2597431707 hasRelatedWork W2102113607 @default.
• W2597431707 hasRelatedWork W2134978580 @default.
• W2597431707 hasRelatedWork W2181027830 @default.
• W2597431707 hasRelatedWork W2517209519 @default.
• W2597431707 hasRelatedWork W3096947959 @default.
• W2597431707 hasRelatedWork W3172783560 @default.
• W2597431707 hasRelatedWork W4285255876 @default.
• W2597431707 hasRelatedWork W4309507688 @default.
• W2597431707 hasVolume "30" @default.
• W2597431707 isParatext "false" @default.
• W2597431707 isRetracted "false" @default.
• W2597431707 magId "2597431707" @default.
• W2597431707 workType "article" @default.